Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018 02; 32(2):210-215.
View in:
PubMed
subject areas
Aged
Benzhydryl Compounds
Cardiovascular Diseases
Cost-Benefit Analysis
Diabetes Mellitus, Type 2
Diabetic Angiopathies
Drug Costs
Female
Glucosides
Humans
Male
Middle Aged
Morbidity
Quality-Adjusted Life Years
Risk Factors
Treatment Outcome
authors with profiles
Erin Weeda